Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing admin@sinochem-nanjing.com 3389378665@qq.com
Follow us:

Dibucaine HCl

    • Product Name Dibucaine HCl
    • Alias Cinchocaine Hydrochloride
    • Einecs 200-168-2
    • Mininmum Order 1 g
    • Factory Site Tengfei Creation Center,55 Jiangjun Avenue, Jiangning District,Nanjing
    • Price Inquiry admin@sinochem-nanjing.com
    • Manufacturer Sinochem Nanjing Corporation
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    582133

    chemical_name Dibucaine Hydrochloride
    cas_number 61-12-1
    molecular_formula C20H29N3O2·HCl
    molecular_weight 379.93 g/mol
    appearance White crystalline powder
    solubility Soluble in water and alcohol
    melting_point 98-100°C
    storage_conditions Store at room temperature, protected from light and moisture
    pharmacological_class Local anesthetic (amide type)
    therapeutic_use Topical analgesic and local anesthetic
    synonyms Cinchocaine hydrochloride
    pKa 8.7
    stability Stable under recommended storage conditions
    odor Odorless
    route_of_administration Topical

    As an accredited Dibucaine HCl factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Dibucaine HCl is packaged in a sealed amber glass bottle containing 25 grams, labeled with product details, safety warnings, and handling instructions.
    Shipping Dibucaine HCl should be shipped in a tightly sealed container, protected from light and moisture. The package must comply with regulatory requirements for hazardous chemicals, including clear labeling. Transport conditions should maintain a cool, dry environment, and the material should be handled by trained personnel using appropriate safety precautions to ensure safe delivery.
    Storage Dibucaine HCl should be stored in a tightly closed container, protected from light and moisture. Keep it at a controlled room temperature, ideally between 20°C and 25°C (68°F–77°F). Store it in a dry, well-ventilated area away from incompatible substances. Ensure access is limited to authorized personnel and clearly label the container to prevent accidental misuse.
    Application of Dibucaine HCl

    Applications of Dibucaine HCl in Industrial Manufacturing

    Dibucaine HCl is a specialized active ingredient with precise applications across several regulated manufacturing sectors, primarily in topical pharmaceutical formulations and veterinary products. As the original manufacturer, we supply material optimized for stability, process control, and reproducibility, supporting rigorous downstream requirements. Below we detail significant application scenarios aligned with relevant industry standards, formulation practices, process integration, and common end-product formats.

    1. Human Pharmaceutical Topical Anesthetics

    Pharmaceutical manufacturers utilize Dibucaine HCl in the formulation of prescription and over-the-counter topical anesthetic creams, ointments, and gels intended for mild surgical procedures, pain relief, and minor skin irritations. Material considerations focus on achieving defined potency and purity in line with strict pharmacopeial standards. Dibucaine HCl is carefully incorporated at controlled stages to ensure efficacy and uniform distribution, with established practices for analytical monitoring through in-process and final QC testing.

    Industry compliance standards

    • United States Pharmacopeia (USP) Monograph on Dibucaine Hydrochloride
    • European Pharmacopoeia (Ph. Eur.) requirements for local anesthetics
    • Current Good Manufacturing Practice (cGMP) per 21 CFR Parts 210/211
    • FDA OTC Drug Monograph for External Analgesics (21 CFR 346)

    Typical usage ratio

    • Formulators typically incorporate Dibucaine HCl at 0.25%–1% w/w depending on the therapeutic target and regulatory maximums, with precise adjustment based on label strength and delivery matrix (cream vs. ointment vs. gel).

    Downstream process integration

    • Manufacturers introduce the ingredient during the final homogenization step to guarantee even distribution throughout oil and water phases, with preceding dissolution in suitable solvents or co-solvents to maximize bioavailability.

    Final product types

    • Rx and OTC topical anesthetic creams
    • Medicated ointments for minor burns and insect bites
    • Gels for dental or skin procedures
    • Minor surgical preparation topicals

    2. Veterinary Topical Preparations

    Veterinary drug manufacturers rely on Dibucaine HCl to formulate numbing, pain-relieving creams and ointments for animal dermatological treatments, wound care, and minor procedures. The primary goal is fast onset and prolonged local action, demanding batch reproducibility and compliance with international veterinary medicine regulations. Extensive compatibility trials ensure integrity across common excipients and animal-safe bases.

    Industry compliance standards

    • Veterinary Medicinal Products Directive 2001/82/EC (EU)
    • US FDA Center for Veterinary Medicine (CVM) Guidance
    • World Organisation for Animal Health (WOAH/OIE) drug standards
    • Good Manufacturing Practice (GMP) as applied to veterinary pharmaceuticals

    Typical usage ratio

    • Producers typically apply 0.2%–1.5% w/w, balancing pain relief requirements for species, with upper limits set by local regulations and pharmacological studies for target animals.

    Downstream process integration

    • Dibucaine HCl joins formulations post-emulsification, under low-shear mixing, to protect chemical integrity and ensure biological activity remains aligned with regulatory test thresholds.

    Final product types

    • Veterinary wound care creams for equines and companion animals
    • Topical gels for livestock pain management
    • Pre- and post-operative local anesthetic ointments for small animals
    • Anti-itch, bite, and sting relief formulations for veterinary use

    3. Hemorrhoidal and Anorectal Therapeutic Products

    Producers of anorectal pharmaceuticals integrate Dibucaine HCl to provide localized analgesia in creams, suppositories, and ointments designed for hemorrhoid and fissure relief. Stringent compliance with both domestic and international quality standards is mandatory due to the sensitive application route and patient population. Controlled dosing and extensive quality assurance processes are essential for reproducible pharmacological profiles across batches.

    Industry compliance standards

    • FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
    • USP standards for hemorrhoidal drug formulations
    • Health Canada Regulations: Natural and Non-prescription Health Products Directorate (NNHPD)
    • ICH Q7 GMP for Active Pharmaceutical Ingredients

    Typical usage ratio

    • Manufacturers utilize 0.25%–1% w/w, adjusted according to final dosage form type and patient safety requirements, ensuring compliance with pharmacopeial monographs and local restrictions.

    Downstream process integration

    • Dibucaine HCl is added during the cooling phase of ointment or suppository base preparation, under closed environment controls, to support uniform dose content and prevent thermal degradation.

    Final product types

    • Hemorrhoidal relief creams and ointments
    • Anorectal suppositories containing local anesthetic
    • Combination analgesic and vasoconstrictor treatments

    4. Topical Anesthetic Patches and Transdermal Delivery

    Manufacturers developing advanced topical systems employ Dibucaine HCl as an active anesthetic component in multi-layered patch designs, targeting sustained action through controlled skin delivery. Integration involves stringent solvent and matrix compatibility studies, alongside validation of active diffusion rates for accurate therapeutic dosing. These systems adhere to strict quality assurance benchmarks due to their regulated status and extended wear periods.

    Industry compliance standards

    • U.S. FDA 21 CFR Part 4 for Combination Products
    • ICH Q8 Pharmaceutical Development for Transdermals
    • Japanese Ministry of Health, Labour and Welfare Transdermal Patch Guidelines
    • ISO 13485 Quality Management for Medical Devices

    Typical usage ratio

    • Active content typically ranges from 1 mg/cm² to 10 mg/cm², varied directly by patch size, patient wear time, and target release profile, with developers referencing in vitro permeation test results to calibrate dosing.

    Downstream process integration

    • Dibucaine HCl is dispersed into the patch reservoir or pressure-sensitive adhesive matrix immediately prior to coating onto release liners, under in-process controls monitoring thickness, content uniformity, and residual solvent levels.

    Final product types

    • Single-use topical anesthetic patches
    • Multi-hour transdermal systems for procedural numbing
    • Patches designed for tattoo and cosmetic procedures
    Free Quote

    Competitive Dibucaine HCl prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.

    We will respond to you as soon as possible.

    Tel: +8615371019725

    Email: admin@sinochem-nanjing.com

    Get Free Quote of Sinochem Nanjing Corporation

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Dibucaine HCl: A Manufacturer’s View on Quality and Application

    Direct Manufacturing Stewardship and Real-World Insights

    Dibucaine HCl starts as a bundle of challenges in the factory. Our team works with the base materials daily, transforming complex organic structures into a consistent batch of pure, white to off-white crystalline powder. Every shift, our senior operators run the reactors with a keen eye on temperature and reaction rates since prolonged exposure or minor impurities can knock the whole process off balance. That sort of hands-on control forms the backbone of any claim we make about purity or reproducibility—no batch sees the warehouse unless it matches our established assay standards and sits tight within our narrow range for melting point and moisture content.

    The product we pack up at the end of the line is Dibucaine hydrochloride under our own label. We hear about the final applications from customers in pharmaceuticals, veterinary clinics, research labs, and sometimes from specialty chemical developers. The immediate reason for its popularity comes down to its potent local anesthetic properties—faster onset, deeper action, and longer duration compared to the older amide anesthetics. Most clients come to us with a long list of competitive products—lidocaine, procaine, tetracaine—but they know what sets Dibucaine apart is not only its strength, but its reliability at low concentrations. That translates into less product usage and fewer procedural interruptions. The way Dibucaine blocks sodium channels outpaces others, giving it a longer window of numbness and making it a staple where prolonged or high-intensity anesthesia is required.

    Why Consistency in Manufacturing Matters

    In our experience, small lot-to-lot variations drastically change user experiences and regulatory compliance outcomes. Pharmaceuticals demand a sharp eye on traceability all the way back to raw inputs. We log everything. Each tank of precursor, each filtration step, and each drying cycle gets a record. This is not just about satisfying audits; it comes from dealing with failed batch issues in the past. We’ve traced obscure defects back to vendor issues or micro-contaminants that crept in during storage. Without this control, the end product won’t dissolve or crystallize right, and sometimes won’t even meet chromatographic purity specs, leaving users scrambling at the formulation stage.

    Quality comes down to the details: HPLC assay, water determination, residual solvents, and specific optical rotations. Our chemists run these tests within hours of production, not days. Heat and light cause Dibucaine HCl to darken or slowly hydrolyze, so we coat our packaging with UV-resistant lining and keep temperature logs through distribution channels. People try to save costs with basic plastic bags or barrels, but a single exposure to high humidity throws off everything from solubility to shelf life.

    We have a standing policy on returned goods—we run them through our analytical suite rather than restocking. Most customers do not see this, though it informs the trust they place in our supply chain. If one batch comes back, we use the data to prevent even a second occurrence. Customers notice this difference, especially those with years in a compounding pharmacy or research lab, where off-odor or color changes often become the start of product rejections.

    Speaking to Differences: Dibucaine HCl Versus Other Local Anesthetics

    Documents alone never explain why Dibucaine HCl leads the pack for certain difficult cases. In the field, physicians and pharmacists run into situations where other anesthetics break down under exposure to bodily fluids, enzymes, or heat. Because of its unique structure—a quinoline ring attached to a diethylamino side—Dibucaine sticks around in tissue noticeably longer, standing up to breakdown better than procaine or even bupivacaine. The pain relief lasts, meaning patients need less frequent dosing, and clinicians trade off risk of toxicity for longer effect, so precise dose calibration becomes essential.

    Our ongoing dialogue with research teams feeds straight back into tweaks we make on the plant floor. During runs when raw materials carry unexpected impurities—say, left over from upstream benzene derivatives—we ramp up on in-line monitoring and revalidation. If you’ve worked in a lab that tests anesthesia strength by cumulative action on muscle tissue, you’ll see that Dibucaine stands apart even at microgram levels. Lower minimum dose means both hospitals and patients avoid side effects like CNS toxicity that crop up with overuse of less potent alternatives.

    It's also worth noting the difference in regulatory attention Dibucaine receives around the world. U.S. markets run headlong into restrictions tied to narrow therapeutic windows. Europe wants longer-term safety data. Other regions focus on cost. Every market variation drives minor plant modifications, from the selection of filtration membranes to the final drying temperature. We don’t just meet an arbitrary standard—we exceed it by default to keep downstream users out of regulatory trouble.

    Experience with Specifications and Usability

    Over years of production, nearly every specification on Dibucaine HCl has been a response to a practical issue. Take solubility: hospitals want injectable formulations to dissolve clear and quick, so our teams work relentlessly on refining particle size during milling. We test batch samples directly in saline and sterile water, not just with chemical solvents in the lab. If it clumps, cakes, or leaves any residue, it gets flagged and never leaves our facility.

    Another practical spec—melting point. Many customers aren’t working in climate-controlled labs. We learned early that batches falling outside the optimal melting point range struggled to perform in compounded preparations, especially in tropical or drafty field settings. The solution required us to modify our vacuum drying stages, not just slap on extra certificate paperwork.

    Moisture content matters, too. Too much moisture, and degradation becomes a real risk. Too little, and the mass becomes nearly statically charged, creating handling problems for automated capsule filling and manual dosing. We discovered this firsthand while supporting a contract manufacturer who kept reporting inconsistent dose weights. By adjusting our own drying process and anti-static protocols, their throughput improved and complaints stopped. These details don’t show up on generic data sheets.

    Our regular clients include industrial labs, generic drug plants, and specialty compounders. Many have stories where the right batch of Dibucaine rescued a full production run after inferior lots from resellers failed test protocols. It pays to buy from direct manufacturers who carry liability on every kilogram, not just traders who offer little in the way of remediation.

    Safety and Handling: Insights from Daily Production

    No production day goes by without a safety briefing about how to handle Dibucaine HCl. Its excellent performance for end users comes with the cost of careful handling for those of us making it. Just a small dusting escapes the containment hood, and the operators can struggle with local numbness for hours. That’s why we invest in specialty air filtration and PPE training for staff. Repeated exposure can sensitize skin or mucous membranes—a lesson learned the hard way in older facilities where floor plans ignored cross-contamination risks.

    Some customers underestimate the powder’s potency and its need for controlled weighing and mixing. We supply advice freely based on our own spill-response drills. Once, a client failed to implement secondary containment in their preparation room. They wound up with high-surface area exposure and reported team-wide symptoms. Sharing our containment protocols and air management procedures gave them a path back to safe handling.

    End User Adaptation and Formulation Experience

    Labs working in formulation and compounding rely on direct feedback—particle morphology, size distribution, ease of solution. If a powder forms lumps, foams on mixing, or behaves unpredictably in simple solvents, it causes massive delays. We’ve been called in on projects where others’ Dibucaine clumped during high-speed mixing, ruining consistency in topical creams or injectable suspensions. Our investments in real-time monitoring, including scanning electron microscopy of batches for particle uniformity, allowed those same clients to reopen their projects and pass final quality controls.

    Volume scalability stands out as a repeated client question. Academic labs love precise microgram samples, while manufacturing partners need multi-kilogram lots that behave the same across months of supply. Because we keep our batch-reactor size moderate, we can maintain the high standard our smaller buyers expect without drift as we pump up volumes for industrial purchasers. It requires careful cross-batch blending and strict hold-point testing, a process many bulk traders gloss over in pursuit of lower pricing.

    Prescribers in the field often ask about excipient compatibility and multi-drug formulation. Over time, our QC teams have developed an internal database logging stability results for over fifty co-formulants. From basic oils and emulsifiers to more complex carrier systems, we provide reference-solubility and precipitation testing results. Sharing these trusted insights helps partners avoid costly, time-consuming pilot runs that might otherwise slow or halt progress.

    Reliability in Large Volume Supply Chains

    Any product with Dibucaine HCl’s profile faces market volatility issues—upstream disruptions in raw material feedstocks hit supply quickly. Our long-term partnerships with upstream producers keep us ahead of sudden shortages. We sign on to annual forecasting models rather than spot buying, keeping inventory buffered even in the face of global price swings. These relationships allow us to step in and stabilize price and supply for longstanding clients when market noise threatens delivery.

    Every time we increase batch frequency or scale, we build in full-spectrum stability studies—a lesson reinforced after several failed stress tests under transport conditions years ago. As temperature and humidity fluctuate during ocean freight, we remain vigilant. Expansive QA oversight ensures no lot heads for export without verifying that days or weeks in transit will not shift assay or visible appearance. Once a batch failed our shipment stress test, and we responded by redesigning our internal packaging and switching to vacuum-sealed foil liners. Those same changes carried over to domestic deliveries, minimizing transit spoilage and waste.

    Environmental Stewardship and Waste Management

    Direct chemical manufacturing of Dibucaine HCl brings a host of environmental responsibilities. Solvent recovery is a major theme in every day’s plan. We invest in closed-loop distillation for the major organic solvents and run spent material through activated carbon treatment. Plant wastewater streams get pH-balanced and sampled continuously to prevent environmental liability. Our operators receive annual training on process-hazard mitigation—not just because regulators require it, but because the future of the site depends on it.

    Over time, we found that switching to greener reagents—not just for the main synthesis but also for intermediates—helped reduce side-stream toxins and cut emissions to almost negligible levels. Some clients even ask for certified green production, and we can document energy use and waste levels batch by batch. These practices grew from hard-won lessons with early regulatory fines and genuine concern from plant staff working daily with production residues.

    Looking Ahead: Innovation and Ongoing Development

    Each season, we see new advances in the literature—adjustments to the pharma-grade pipeline, tweaks in route optimization, and tougher global regulatory standards. Our in-house R&D team takes these advances and adapts them to the production floor. Whenever a new impurity profile emerges from regulators, we adjust our analytic standards and train staff hands-on, not just by memo.

    Recently, interest in longer-acting pain relief and rapid-dissolving topical systems has driven requests for custom-milled dibucaine. Smaller particle size lends itself to rapid absorption but complicates handling. We support pilot runs in our own labs, providing customers with as much hands-on advice as they want. Knowledge from real-world production allows us to give specialty clients insight into how subtle chemical tweaks play out on large-scale reactors, not just in test tubes.

    Transparency on Challenges and Solutions

    Manufacturing Dibucaine HCl is rarely smooth sailing. Supply chain hiccups, on-site accidents, and regulatory curveballs remain part of our everyday business life. Some years back, a precursor impurity slipped past our incoming inspection. Within days, multiple batches failed final assay, teaching us to layer redundant tests and to trust but verify every step of the way. We now carry out random spot-checks even after vendors qualify, catching variations faster than before.

    Document updates and regulatory submissions can take a toll, especially as standards grow more exacting and new end uses appear. We hire staff who value correction and precision, because the factory floor leaves little room for error. It takes a rare mix of endurance and adaptability to work with such a potent compound, and we support our crew with ongoing training and open feedback channels. Mistakes do happen; our ethos emphasizes quick reporting and structured follow-up over punitive response.

    Industry Relevance and Real-World Dependability

    In nearly two decades of supplying Dibucaine HCl, we’ve watched the market expand from small specialty use to high-volume essential supply. Every customer, from hospital pharmacies to global drug producers, values more than just a price point. Real value means they get a stable, safe, high-purity anesthetic ready for their toughest applications—without question marks on supply or regulatory fit.

    We remain rooted as the hands-on manufacturer, learning and adapting each year. From shifting quality targets to evolving environmental standards, our familiarity with both the factory floor and customer goals shapes every kilogram we ship. Dibucaine HCl means more than a chemical in our system—it’s a benchmark for safety, reliability, and performance shaped by real experience and continuous improvement.